TTrialPathMatch Me to Trials
← Back to trials
RecruitingPDACPDAC - Pancreatic Ductal AdenocarcinomaNSCLC

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Eligible age

18+ yrs

Accepts

All genders

Locations

15 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.

Sponsor: Tango Therapeutics, Inc.

You may qualify if…

  • ✓ 1. Is ≥18 years of age at the time of signature of the main study ICF.
  • ✓ 2. Has an ECOG PS of 0 or 1.
  • ✓ 3. Has a tumor with loss of MTAP protein or bi-allelic deletion of the MTAP gene
  • ✓ 4. Arms A and B only: Has a tumor with a RAS mutation
  • ✓ 5. Pathologically documented metastatic PDAC or locally advanced, recurrent or metastatic NSCLC
  • ✓ 6. Has received prior standard therapy
  • ✓ 7. Arms A and B only: Must not have received prior RAS-targeted therapy
  • ✓ 8. Has evidence of measurable disease based on RECIST v1.1.

You may not qualify if…

  • ✕ 1. Has received prior treatment with a PRMT5 inhibitor, or MAT2A inhibitor
  • ✕ 2. Arms A and B only: Prior enrollment in any phase 3 clinical trial of RMC-6236 or RMC-9805
  • ✕ 3. Known allergy, hypersensitivity or intolerance to TNG462 (all arms), RMC-6236 Arm A), RMC-9805 (Arm B), mFOLFIRINOX (Arm C), gemcitabine/nab-paclitaxel (Arm D) or their excipients
  • ✕ 4. Has uncontrolled intercurrent illness that will limit compliance with the study requirements.
  • ✕ 5. Has an active infection requiring systemic therapy.
  • ✕ 6. Is currently participating in or has planned concurrent participation in a study of another investigational agent or device.
  • ✕ 7. Has impairment of GI function or disease that may significantly alter the absorption of the oral medications
  • ✕ 8. Has known or suspected active or untreated CNS metastases associated with progressive neurological symptoms

Where it's recruiting

Arizona

Scottsdale

Colorado

Denver

District of Columbia

Washington D.C.

Florida

Jacksonville

Illinois

Chicago

Indiana

Indianapolis

Iowa

Iowa City

Minnesota

Rochester

New York

New York

North Carolina

Chapel Hill

Source: ClinicalTrials.gov · NCT06922591 · last updated 2026-10-23

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Com · TrialPath